Our top pick for
Cinedigm Corp is an entertainment business based in the US. Cinedigm shares (CIDM) are listed on the NASDAQ and all prices are listed in US Dollars. Cinedigm employs 68 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.56|
|52-week range||$0.45 - $2.81|
|50-day moving average||$2.28|
|200-day moving average||$1.64|
|Wall St. target price||$4.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||7.11%|
|1 month (2021-09-23)||1.99%|
|3 months (2021-07-23)||75.34%|
|6 months (2021-04-23)||88.24%|
|1 year (2020-10-23)||345.22%|
|2 years (2019-10-23)||161.01%|
|3 years (2018-10-23)||86.86%|
|5 years (2016-10-21)||38.38%|
Valuing Cinedigm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cinedigm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cinedigm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $237,000.
The EBITDA is a measure of a Cinedigm's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$40.4 million|
|Gross profit TTM||$15.3 million|
|Return on assets TTM||-5.27%|
|Return on equity TTM||-345.71%|
|Market capitalisation||$404.7 million|
TTM: trailing 12 months
There are currently 3.9 million Cinedigm shares held short by investors – that's known as Cinedigm's "short interest". This figure is 13.4% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Cinedigm shares can be evaluated.
Cinedigm's "short interest ratio" (SIR) is the quantity of Cinedigm shares currently shorted divided by the average quantity of Cinedigm shares traded daily (recently around 12.7 million). Cinedigm's SIR currently stands at 0.31. In other words for every 100,000 Cinedigm shares traded daily on the market, roughly 310 shares are currently held short.
However Cinedigm's short interest can also be evaluated against the total number of Cinedigm shares, or, against the total number of tradable Cinedigm shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cinedigm's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cinedigm shares in existence, roughly 20 shares are currently held short) or 0.028% of the tradable shares (for every 100,000 tradable Cinedigm shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cinedigm.
Find out more about how you can short Cinedigm stock.
We're not expecting Cinedigm to pay a dividend over the next 12 months.
Cinedigm's shares were split on a 1:10 basis on 9 May 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cinedigm shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cinedigm shares which in turn could have impacted Cinedigm's share price.
Over the last 12 months, Cinedigm's shares have ranged in value from as little as $0.45 up to $2.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cinedigm's is 1.5937. This would suggest that Cinedigm's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cinedigm Corp. , together with its subsidiaries, operates as distributor and aggregator of independent movie, television, and other short form content in the United States, Canada, and New Zealand. The company operates through two segments, Cinema Equipment Business and Media Content and Entertainment Business. The company distributes its products for various brands, such as Hallmark, Televisa, ITV, Nelvana, ZDF, Konami, NFL, and NHL, as well as international and domestic content creators, movie producers, television producers, and other short form digital content producers. It also collaborates with producers, various brands, and other content owners to market, source, curate, and distribute content to targeted audiences through existing and emerging digital home entertainment platforms, including Apple, Amazon Prime, Netflix, Hulu, Xbox, Tubi, PlutoTV, Vudu, and cable/satellite video-on-demand; and distributes DVD and Blu-ray discs to wholesalers and retailers with sales coverage to approximately 48,000 retail storefronts, including Walmart, Target, Best Buy, and Amazon. In addition, the company operates various branded and curated over-the-top (OTT) entertainment channels, including Docurama, CONtv, Dove Channel, Viewster Anime, Fandor, and Screambox; and Matchpoint, a software-as-a-service platform to automate the distribution of streaming content and OTT channels. Cinedigm Corp.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.